Enfortumab vedotin is indicated as a monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received platinum-containing chemotherapy and a PD-1/L1 inhibitor. Its antitumor activity is mediated through binding to Nectin-4-expressing cells, followed by internalization and release of the cytotoxic agent monomethyl auristatin E (MMAE), leading to cell cycle arrest and apoptotic cell death.